Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

Amarin to Present at the Canaccord Genuity 33rd Annual Growth Conference



Amarin to Present at the Canaccord Genuity 33rd Annual Growth Conference

BEDMINSTER, N.J. and DUBLIN, Ireland, Aug. 13, 2013 (GLOBE NEWSWIRE) -- Amarin
Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the
commercialization and development of therapeutics to improve cardiovascular
health, announced that John F. Thero, Amarin's President, is scheduled to
present a general company update at the Canaccord Genuity 33rd Annual Growth
Conference on Thursday, August 15, 2013, at 4:00 p.m. ET.

A live audio webcast of the presentation will be available at:

http://wsw.com/webcast/canaccord10/amrn/

About Amarin

Amarin Corporation plc is a biopharmaceutical company focused on the
commercialization and development of therapeutics to improve cardiovascular
health. Amarin's product development program leverages its extensive
experience in lipid science and the potential therapeutic benefits of
polyunsaturated fatty acids. Vascepa^® (icosapent
ethyl), Amarin's first FDA approved product, is a patented, ultra pure omega-3
fatty acid product comprising not less than 96% EPA and is available by
prescription. For more information about Vascepa visit www.vascepa.com. For
more information about Amarin visit www.amarincorp.com.

CONTACT: Joseph Bruno
         Investor Relations and Corporate Communications
         Amarin Corporation
         In U.S.: +1 (908) 719-1315
         investor.relations@amarincorp.com

company logo
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement